<DOC>
	<DOCNO>NCT02713126</DOCNO>
	<brief_summary>Participants heart failure preserve ejection fraction undergo 12 week cardiac rehabilitation exercise training ( ET ) randomize either nebulized sodium nitrite inhalation solution placebo inhalation solution ( normal saline ) training period . Study drug administer 3 time daily daytime hour one dose immediately prior onset ET session throughout 12 week trial . The objective determine inhale sodium nitrite improves clinical response tolerability ET .</brief_summary>
	<brief_title>Inorganic Nitrite Amplify Benefits Tolerability Exercise Training HFpEF ( INABLE-Training )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Age ≥ 50 year Symptoms dyspnea ( IIIV ) without evidence noncardiac ischemic explanation dyspnea Ejection Fraction ( EF ) ≥ 50 % One following : Previous hospitalization Heart Failure ( HF ) radiographic evidence ( pulmonary venous hypertension , vascular congestion , interstitial edema , pleural effusion ) pulmonary congestion Catheterization document elevated filling pressure rest ( Pulmonary Capillary Wedge Pressure ( PCWP ) = ≥15 Left Ventricular EndDiastolic Pressure ( LVEDP ) ≥18 ) exercise ( PCWP ≥25 ) Elevated Natruretic PeptideproBNP ( &gt; 400 pg/ml ) BType Natriuretic Peptide ( BNP ) ( &gt; 200 pg/ml ) Echo evidence diastolic dysfunction/elevated filling pressure manifest medial E/e ' ratio≥15 and/or leave atrial enlargement chronic treatment diuretic sign symptom heart failure Heart failure primary factor limit activity indicate answer # 2 follow question : My ability active limit : 1 . Joint , foot , leg , hip back pain 2 . Shortness breath and/or fatigue and/or chest pain 3 . Unsteadiness dizziness 4 . Lifestyle , weather , I n't like active No chronic nitrate therapy use intermittent sublingual nitroglycerin ( requirement &gt; 1 sublingual nitroglycerin per week ) . No daily use phosphodiesterase 5 ( PDE5 ) inhibitor soluble guanylyl cyclase activator willing withhold need use PDE5 inhibitor duration study Ambulatory ( wheelchair / scooter dependent ) Body size allow wear accelerometer belt confirm ability comfortably fasten test belt provide screening process . Willingness wear accelerometer belt duration trial Recent ( &lt; 1 month ) hospitalization heart failure Ongoing requirement PDE5 inhibitor , organic nitrate soluble guanylyl cyclase activator Hemoglobin ( Hgb ) &lt; 8.0 g/dl within 30 day prior randomization Glomerular Filtration Rate ( GFR ) &lt; 20 ml/min/1.73 m2 within 30 day prior randomization Systolic blood pressure &lt; 115 mmHg seat &lt; 90 mmHg stand Resting Heart Rate &gt; 110 Previous adverse reaction study drug necessitate withdrawal therapy Significant chronic obstructive pulmonary disease primary contributor symptom , opinion Investigator . Ischemia think contribute dyspnea , opinion Investigator . Documentation previous Ejection Fraction &lt; 40 % Acute coronary syndrome within 3 month define electrocardiographic ( ECG ) change biomarkers myocardial necrosis ( e.g. , troponin ) appropriate clinical setting ( chest discomfort anginal equivalent ) Percutaneous Coronary Intervention , coronary artery bypass grafting , new biventricular pacing within past 3 month Obstructive hypertrophic cardiomyopathy Known infiltrative cardiomyopathy ( amyloid ) Constrictive pericarditis tamponade Active myocarditis Complex congenital heart disease Active collagen vascular disease More mild aortic mitral stenosis Intrinsic ( prolapse , rheumatic ) valve disease moderate mitral , tricuspid aortic regurgitation Acute chronic severe liver disease evidence follow : encephalopathy , variceal bleeding , International Normalized Ratio ( INR ) &gt; 1.7 absence anticoagulation treatment Terminal illness ( HF ) expect survival less 1 year Regularly ( &gt; 1x per week ) swim water aerobics Enrollment plan enrollment another therapeutic clinical trial next 3 month . Inability comply plan study procedure Pregnancy breastfeed mother</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>